News

An analysis of chest X-rays suggests people of color are more likely to have increased disease severity.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

The indication limits the new opioid to clinical setting use—no take-home prescriptions.

A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.

A new study has great implications for equitable access to primary care for older adults during the pandemic.

In a pair of studies, 42% of patients and care partners reported having no current treatment.

A leading psychiatric expert discusses some of the pitfalls people face due to the ongoing pandemic.

Approximately half of depression patients do not sufficiently benefit after treated with electroconvulsive therapy, leading to high rates of relapses.

Firmicutes bacteria can help produce metabolites that maintain intestinal barriers and mucosal immunity.

New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.

It is important for clinicians considering prescribing denosumab treatment to counsel patients before its initiation on the importance of not delaying or discontinuing injections.

Approximately 5% of the 13,000 TBI patients examined died during the course of the study.

The level of distress for adults in the UK rose from 18.9% in 2018-19 to 27.3% in April.

World-leading virologist and AIDS researcher David Ho, MD, joins the inaugural podcast episode.

The fast-acting therapy has been long-discussed for its unique benefits to severe patients—as well as notable concerns surrounding its administration.

There is a higher prevalence of IBS found in women than men.

The pandemic has burdened blood drives nationally. A new sickle cell drug keeps patients from needing as many transfusions.

A telehealth group showed better outcomes than an in-person training group for some variables of communication skills for individuals who suffered a traumatic brain injury.

The expansion makes history for the injection biologic.

There has been controversy over the efficacy and safety of step-therapy for neovascular age-related macular degeneration.

A new systematic review and meta-analysis challenges the notion that preventing VTE is associated reduced mortality risk.

How has the new agent fared in its indicated patients in its first year on the market?

The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.

In a phase 1b study presented virtually during ASRS 2020, investigators found a reduction in central subfield thickness after 12 weeks of OPT-302 combined with aflibercept injections.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

The mean number of injections in the studies over 12 months was 9.36 ± 2.66, with a mean change in ETDRS letters was 7.86 ± 1.37.

New phase 1/2 data shows AAV-RGPR may benefit a previously untreated population of inherited retina disease boys and young men.

As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.

New findings evidences the device commonly used treatment in patients with VTE—despite its association with potentially new DVT development or existing DVT propagation.